文献速递瓣膜病与结构性心脏病

感染性心内膜炎面临的挑战

Challenges in Infective Endocarditis.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

本文综述感染性心内膜炎在病因、临床表现和病程上的异质性,指出其常于医疗保健环境中获得、超过半数病例无已知心脏病,尽管优化治疗1年死亡率仍接近30%。金黄色葡萄球菌已成为发达国家主要致病菌,导致侵袭性疾病且多见于脆弱或老年人群;缺乏研究基础设施与经费、随机对照试验少,手术时机和抗生素预防等长期争议未解决。

要点

  • 感染性心内膜炎常于医疗保健环境中获得,超过半数病例无已知心脏病。
  • 尽管优化治疗,1年死亡率仍接近30%。
  • 金黄色葡萄球菌已成为发达国家主要致病菌,导致侵袭性疾病且多见于脆弱或老年人群。

核心结论

  • 感染性心内膜炎在病因、临床表现和病程上具有异质性,尽管优化治疗1年死亡率仍接近30%,其带来的挑战显著。

研究设计与样本

  • 本文为综述,回顾感染性心内膜炎面临的挑战并概述当前和未来的应对策略。

主要发现

  • 感染性心内膜炎常于医疗保健环境中获得,超过半数病例发生在无已知心脏病的患者中。
  • 尽管优化治疗,1年死亡率仍接近30%。
  • 金黄色葡萄球菌已成为发达国家主要致病菌,导致侵袭性疾病且多见于脆弱或老年人群。
  • 缺乏研究基础设施与经费,指导实践的随机对照试验少。
  • 手术时机和抗生素预防作用等长期争议尚未解决。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Infective endocarditis is defined by a focus of infection within the heart and is a feared disease across the field of cardiology. It is frequently acquired in the health care setting, and more than one-half of cases now occur in patients without known heart disease. Despite optimal care, mortality approaches 30% at 1 year. The challenges posed by infective endocarditis are significant. It is heterogeneous in etiology, clinical manifestations, and course. Staphylococcus aureus, which has become the predominant causative organism in the developed world, leads to an aggressive form of the disease, often in vulnerable or elderly patient populations. There is a lack of research infrastructure and funding, with few randomized controlled trials to guide practice. Longstanding controversies such as the timing of surgery or the role of antibiotic prophylaxis have not been resolved. The present article reviews the challenges posed by infective endocarditis and outlines current and future strategies to limit its impact.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Cahill TJ, Baddour LM, Habib G, et al. Challenges in Infective Endocarditis. J Am Coll Cardiol. 2017. PMID: 28104075. doi:10.1016/j.jacc.2016.10.066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。